Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Actavis to acquire Forest Laboratories for approximately $25 billion, or $89.48 per Forest share consisting of $26.04 in cash and 0.3306 Actavis shares for…
Actavis acquired Forest Laboratories for $20.7B.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Actavis acquired Forest Laboratories for approximately $25B ($28.38 per share in cash and stock). Deal announced February 2014, closed June 2014. The acquisition gave Actavis Forest's branded pharmaceutical portfolio including Namenda (memantine) and pipeline assets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Actavis plc / Forest Laboratories, Inc. (this deal) | 2014 | $25.0B | 75 |
| Actavis plc / Warner Chilcott plc | 2013 | $8.5B | 63 |
| Actavis plc / Allergan plc | 2014 | $70.5B | 61 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
← Browse all deals · How we score deals
More: 2014 deals · Actavis plc deals · Neurology deals